United Therapeutics Corporation (UTHR) stock price, chart and research
United Therapeutics Corporation (UTHR) last traded at $582.46 at the close on November 9, 2026, up $20.44 (3.64%) on the day.
- Day range: $556.63 to $586.46
- 52-week range: $445.81 to $614.23
- Market cap: $24.81 billion
- P/E (trailing 12 months): 21.99
- Forward P/E: 16.83
- EPS (trailing 12 months): $26.49
- Dividend yield: 0.00%
- Volume: 559,567 shares
About United Therapeutics Corporation
Sector: Healthcare; industry: Drug Manufacturers - Specialty & Generic; headquarters: United States; CEO: Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.; 1,400 employees; listed since 1999-06-17.
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products,…
Financials
Revenue over the last 12 months was $3.19 billion, net income $1.23 billion, a profit margin of 38.6%. Revenue grew 1.9% from a year earlier.
Institutional owners of UTHR (13F)
Tracked managers holding UTHR in 13F filings for the quarter ending 2026-09-30:
- Dimensional Fund Advisors LP: $292.9 million, 0.05% of its portfolio (added)
- IMC-Chicago, LLC: $4.5 million, 0.04% of its portfolio (added)
ETFs that hold UTHR
Research UTHR with LunaTerminal
- Interactive chart from one day to ten years, with volume, technicals and comparisons.
- Valuation, analyst ratings, dividends, earnings history and recent news.
- Ask LunaTerminal about UTHR: AI answers that cite dated data; no account needed for 5 prompts
- 13F filings: which managers own what
- How advisors use LunaTerminal for market research
Market data via Fear & Greed (feargreedflow.com); 13F holdings from SEC filings. Market data can be delayed; check dates before relying on a figure. Answers are research, not financial advice.